EP2686320A1 - Inhibiteurs de la gyrase tricyclique - Google Patents
Inhibiteurs de la gyrase tricycliqueInfo
- Publication number
- EP2686320A1 EP2686320A1 EP12710633.4A EP12710633A EP2686320A1 EP 2686320 A1 EP2686320 A1 EP 2686320A1 EP 12710633 A EP12710633 A EP 12710633A EP 2686320 A1 EP2686320 A1 EP 2686320A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- optionally substituted
- mmol
- amine
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002271 gyrase inhibitor Substances 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 420
- 238000000034 method Methods 0.000 claims abstract description 89
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 239000000651 prodrug Substances 0.000 claims abstract description 15
- 229940002612 prodrug Drugs 0.000 claims abstract description 15
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims description 137
- 150000003335 secondary amines Chemical class 0.000 claims description 55
- -1 aminocyclopropyl Chemical group 0.000 claims description 50
- 125000004429 atom Chemical group 0.000 claims description 50
- 150000003512 tertiary amines Chemical class 0.000 claims description 45
- 125000001072 heteroaryl group Chemical group 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 36
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 125000005842 heteroatom Chemical group 0.000 claims description 36
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 229910052717 sulfur Inorganic materials 0.000 claims description 32
- 150000001412 amines Chemical class 0.000 claims description 27
- 125000004122 cyclic group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 125000006239 protecting group Chemical group 0.000 claims description 22
- 230000008569 process Effects 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- SEOZPKYDFRZJMV-UHFFFAOYSA-N 3-[(2-oxo-1,3-oxazolidin-3-yl)phosphanyl]-1,3-oxazolidin-2-one Chemical compound O=C1OCCN1PN1C(=O)OCC1 SEOZPKYDFRZJMV-UHFFFAOYSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 13
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 8
- 108010054814 DNA Gyrase Proteins 0.000 claims description 7
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 7
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 6
- 125000004434 sulfur atom Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 239000012964 benzotriazole Substances 0.000 claims description 4
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000000716 hydrazinylidene group Chemical group [*]=NN([H])[H] 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- UHCBBWUQDAVSMS-UHFFFAOYSA-N fluoroethane Chemical compound CCF UHCBBWUQDAVSMS-UHFFFAOYSA-N 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 3
- 125000001041 indolyl group Chemical group 0.000 claims description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 3
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical compound N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 claims description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims description 2
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 claims description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical group COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 claims description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- AOJDZKCUAATBGE-UHFFFAOYSA-N bromomethane Chemical compound Br[CH2] AOJDZKCUAATBGE-UHFFFAOYSA-N 0.000 claims 1
- HFPGRVHMFSJMOL-UHFFFAOYSA-N dibromomethane Chemical compound Br[CH]Br HFPGRVHMFSJMOL-UHFFFAOYSA-N 0.000 claims 1
- 125000000565 sulfonamide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 265
- 239000000203 mixture Substances 0.000 description 187
- 239000000243 solution Substances 0.000 description 161
- 239000007787 solid Substances 0.000 description 104
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 102
- 235000019439 ethyl acetate Nutrition 0.000 description 97
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 78
- 229940093499 ethyl acetate Drugs 0.000 description 71
- 238000002360 preparation method Methods 0.000 description 68
- 238000006243 chemical reaction Methods 0.000 description 67
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- 238000005160 1H NMR spectroscopy Methods 0.000 description 54
- 239000011541 reaction mixture Substances 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000012044 organic layer Substances 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 41
- 229910000027 potassium carbonate Inorganic materials 0.000 description 37
- 239000005457 ice water Substances 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 239000011734 sodium Substances 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 32
- 239000000725 suspension Substances 0.000 description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 25
- 238000004587 chromatography analysis Methods 0.000 description 23
- 238000004128 high performance liquid chromatography Methods 0.000 description 22
- 239000000543 intermediate Substances 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 21
- 238000003786 synthesis reaction Methods 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 19
- 239000013058 crude material Substances 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- 238000004440 column chromatography Methods 0.000 description 17
- 239000012043 crude product Substances 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 239000012230 colorless oil Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 239000002244 precipitate Substances 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 11
- 150000003141 primary amines Chemical class 0.000 description 11
- 238000002390 rotary evaporation Methods 0.000 description 11
- 238000005481 NMR spectroscopy Methods 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 9
- 150000004985 diamines Chemical class 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 238000003818 flash chromatography Methods 0.000 description 9
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 8
- 208000035143 Bacterial infection Diseases 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 208000022362 bacterial infectious disease Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 8
- 239000008241 heterogeneous mixture Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- OHFVPBGSKPYIED-UHFFFAOYSA-N 2-methylpyrimidin-5-ol Chemical compound CC1=NC=C(O)C=N1 OHFVPBGSKPYIED-UHFFFAOYSA-N 0.000 description 7
- 108010041052 DNA Topoisomerase IV Proteins 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 229910019213 POCl3 Inorganic materials 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000375 suspending agent Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- IAXKDYYTMWUUIA-HSUXUTPPSA-N (1r,4r,5r)-2-azabicyclo[2.2.1]heptan-5-amine Chemical compound C1[C@@H](N)[C@@]2([H])CN[C@]1([H])C2 IAXKDYYTMWUUIA-HSUXUTPPSA-N 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 5
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 5
- 241000589602 Francisella tularensis Species 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000006184 cosolvent Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VARHTVWSJWDTKW-UHFFFAOYSA-N tert-butyl n-(2-amino-3-cyano-5-fluoro-1h-indol-7-yl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC(F)=CC2=C1NC(N)=C2C#N VARHTVWSJWDTKW-UHFFFAOYSA-N 0.000 description 5
- VIDZIQBTIMICAK-UHFFFAOYSA-N tert-butyl n-(3,5-difluoro-2-nitrophenyl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC(F)=CC(F)=C1[N+]([O-])=O VIDZIQBTIMICAK-UHFFFAOYSA-N 0.000 description 5
- KCRHGAHTZOQCCT-UHFFFAOYSA-N tert-butyl n-[2,4-bis(benzylsulfanyl)-6-fluoro-9h-pyrimido[4,5-b]indol-8-yl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=CC(F)=CC(C2=C(SCC=3C=CC=CC=3)N=3)=C1NC2=NC=3SCC1=CC=CC=C1 KCRHGAHTZOQCCT-UHFFFAOYSA-N 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- 244000034356 Aframomum angustifolium Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- HUFZFDHVSTXCAY-KJXAQDMKSA-N benzyl (1r,4r,5r)-5-[4-methoxy-n-[(2-methylpropan-2-yl)oxycarbonyl]anilino]-2-azabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C([C@@]1([C@@H](C[C@@]2([H])C1)N(C(=O)OC(C)(C)C)C=1C=CC(OC)=CC=1)[H])N2C(=O)OCC1=CC=CC=C1 HUFZFDHVSTXCAY-KJXAQDMKSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000006073 displacement reaction Methods 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000011369 resultant mixture Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- QIYOMZXJQAKHEK-UHFFFAOYSA-N tert-butyl n-(3-azabicyclo[3.1.0]hexan-6-yl)carbamate Chemical compound C1NCC2C(NC(=O)OC(C)(C)C)C21 QIYOMZXJQAKHEK-UHFFFAOYSA-N 0.000 description 4
- VERHYGQTHIOMQC-IWSPIJDZSA-N tert-butyl n-[(1r,4r,5r)-2-azabicyclo[2.2.1]heptan-5-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)[C@@]2([H])CN[C@]1([H])C2 VERHYGQTHIOMQC-IWSPIJDZSA-N 0.000 description 4
- CGEBPOMWRHSMLI-QMMMGPOBSA-N tert-butyl n-[(7r)-5-azaspiro[2.4]heptan-7-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CNCC11CC1 CGEBPOMWRHSMLI-QMMMGPOBSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- HTFNVAVTYILUCF-UHFFFAOYSA-N 2-[2-ethoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methyl-11-methylsulfonylpyrimido[4,5-b][1,4]benzodiazepin-6-one Chemical compound CCOc1cc(ccc1Nc1ncc2N(C)C(=O)c3ccccc3N(c2n1)S(C)(=O)=O)C(=O)N1CCC(CC1)N1CCN(C)CC1 HTFNVAVTYILUCF-UHFFFAOYSA-N 0.000 description 3
- NVYMOVCPYONOSF-UHFFFAOYSA-N 2-aminopyrimidin-5-ol Chemical compound NC1=NC=C(O)C=N1 NVYMOVCPYONOSF-UHFFFAOYSA-N 0.000 description 3
- HJKZGKMJUUPEGQ-UHFFFAOYSA-N 3,5-difluoro-n-methyl-2-nitroaniline Chemical compound CNC1=CC(F)=CC(F)=C1[N+]([O-])=O HJKZGKMJUUPEGQ-UHFFFAOYSA-N 0.000 description 3
- NLMQHXUGJIAKTH-UHFFFAOYSA-N 4-hydroxyindole Chemical compound OC1=CC=CC2=C1C=CN2 NLMQHXUGJIAKTH-UHFFFAOYSA-N 0.000 description 3
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 240000000662 Anethum graveolens Species 0.000 description 3
- 241000581608 Burkholderia thailandensis Species 0.000 description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000495778 Escherichia faecalis Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000011914 asymmetric synthesis Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000003637 basic solution Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000002447 crystallographic data Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 2
- FVLYPXOSHYZOPT-LURJTMIESA-N (2s)-2-(1,3-dioxoisoindol-2-yl)propanoyl chloride Chemical compound C1=CC=C2C(=O)N([C@@H](C)C(Cl)=O)C(=O)C2=C1 FVLYPXOSHYZOPT-LURJTMIESA-N 0.000 description 2
- HGOQIVARGHXIRS-DSYKOEDSSA-N (3ar,4r,6as)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-amine Chemical compound C1NC[C@@H]2[C@H](N)CC[C@@H]21 HGOQIVARGHXIRS-DSYKOEDSSA-N 0.000 description 2
- OQKBLBZCSUDXFC-JMMWHDCWSA-N (6r)-3-azabicyclo[3.2.0]heptan-6-amine Chemical compound C1NCC2[C@H](N)CC21 OQKBLBZCSUDXFC-JMMWHDCWSA-N 0.000 description 2
- ZNBAIDAZWXVTFV-RXMQYKEDSA-N (7r)-2-azaspiro[3.3]heptan-7-amine Chemical compound N[C@@H]1CCC11CNC1 ZNBAIDAZWXVTFV-RXMQYKEDSA-N 0.000 description 2
- HGOQIVARGHXIRS-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-4-amine Chemical compound C1NCC2C(N)CCC21 HGOQIVARGHXIRS-UHFFFAOYSA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- CQMJEZQEVXQEJB-UHFFFAOYSA-N 1-hydroxy-1,3-dioxobenziodoxole Chemical compound C1=CC=C2I(O)(=O)OC(=O)C2=C1 CQMJEZQEVXQEJB-UHFFFAOYSA-N 0.000 description 2
- NTYOXGALQDHZEW-UHFFFAOYSA-N 2-(1-hydroxyethyl)pyrimidin-5-ol Chemical compound CC(O)C1=NC=C(O)C=N1 NTYOXGALQDHZEW-UHFFFAOYSA-N 0.000 description 2
- UOXJNGFFPMOZDM-UHFFFAOYSA-N 2-[di(propan-2-yl)amino]ethylsulfanyl-methylphosphinic acid Chemical compound CC(C)N(C(C)C)CCSP(C)(O)=O UOXJNGFFPMOZDM-UHFFFAOYSA-N 0.000 description 2
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 229910006124 SOCl2 Inorganic materials 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 2
- 229940073608 benzyl chloride Drugs 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 239000012456 homogeneous solution Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 150000002475 indoles Chemical group 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 125000005647 linker group Chemical group 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 125000002950 monocyclic group Chemical class 0.000 description 2
- DJYHGMUZFIJVQH-UHFFFAOYSA-N n-methyl-5-phenylmethoxypyrimidin-2-amine Chemical compound C1=NC(NC)=NC=C1OCC1=CC=CC=C1 DJYHGMUZFIJVQH-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- UHSGELRYPQABHF-FSDSQADBSA-N (1r,5s,7r)-5-methyl-3-azabicyclo[3.2.0]heptan-7-amine Chemical compound C1NC[C@]2(C)[C@H]1[C@H](N)C2 UHSGELRYPQABHF-FSDSQADBSA-N 0.000 description 1
- OQKBLBZCSUDXFC-NGJCXOISSA-N (1s,5r,6r)-3-azabicyclo[3.2.0]heptan-6-amine Chemical compound C1NC[C@@H]2[C@H](N)C[C@@H]21 OQKBLBZCSUDXFC-NGJCXOISSA-N 0.000 description 1
- ILZZJZJQDKNJOH-LWOQYNTDSA-N (2r)-5-azaspiro[2.4]heptan-2-amine Chemical compound N[C@@H]1CC11CNCC1 ILZZJZJQDKNJOH-LWOQYNTDSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YETODIXQMRZKEG-RITPCOANSA-N (3ar,6ar)-1,2,3,3a,4,5,6,6a-octahydropyrrolo[2,3-c]pyrrole Chemical compound C1NC[C@@H]2NCC[C@@H]21 YETODIXQMRZKEG-RITPCOANSA-N 0.000 description 1
- UOQFURHMDNIQBW-NKWVEPMBSA-N (3ar,6ar)-3a-methyl-2,3,4,5,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrole Chemical compound C1CN[C@H]2CNC[C@]21C UOQFURHMDNIQBW-NKWVEPMBSA-N 0.000 description 1
- UMSJKXQIBQAXDE-NKWVEPMBSA-N (3s,4r)-6-azaspiro[3.4]octan-3-amine Chemical compound N[C@H]1CC[C@@]11CNCC1 UMSJKXQIBQAXDE-NKWVEPMBSA-N 0.000 description 1
- PTDVPWWJRCOIIO-UHFFFAOYSA-N (4-methoxyphenyl)methanethiol Chemical compound COC1=CC=C(CS)C=C1 PTDVPWWJRCOIIO-UHFFFAOYSA-N 0.000 description 1
- PGIMFPIFSQGCDL-YFKPBYRVSA-N (4r)-6-azaspiro[2.4]hept-1-en-4-amine Chemical compound N[C@H]1CNCC11C=C1 PGIMFPIFSQGCDL-YFKPBYRVSA-N 0.000 description 1
- ZNBAIDAZWXVTFV-YFKPBYRVSA-N (7s)-2-azaspiro[3.3]heptan-7-amine Chemical compound N[C@H]1CCC11CNC1 ZNBAIDAZWXVTFV-YFKPBYRVSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- DKVDSNMJXDQNCD-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinazoline Chemical compound N1=CN=CC2=C(NC=C3)C3=CC=C21 DKVDSNMJXDQNCD-UHFFFAOYSA-N 0.000 description 1
- JILNIZGVLASAPX-UHFFFAOYSA-N 2,3-bis(sulfanylmethyl)but-2-ene-1,4-dithiol Chemical compound SCC(CS)=C(CS)CS JILNIZGVLASAPX-UHFFFAOYSA-N 0.000 description 1
- FHQRXRBLNUUCQC-UHFFFAOYSA-N 2,4-dichloro-6-fluoro-8-methyl-9h-pyrimido[4,5-b]indole Chemical compound N1C2=NC(Cl)=NC(Cl)=C2C2=C1C(C)=CC(F)=C2 FHQRXRBLNUUCQC-UHFFFAOYSA-N 0.000 description 1
- RHZBRCQIKQUQHQ-UHFFFAOYSA-N 2-(1,3-dioxoisoindol-2-yl)acetyl chloride Chemical compound C1=CC=C2C(=O)N(CC(=O)Cl)C(=O)C2=C1 RHZBRCQIKQUQHQ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- DAQNWAZKLBDTFO-UHFFFAOYSA-N 2-(2-hydroxypropan-2-yl)pyrimidin-5-ol Chemical compound CC(C)(O)C1=NC=C(O)C=N1 DAQNWAZKLBDTFO-UHFFFAOYSA-N 0.000 description 1
- WQWNWDNCJLEPJK-UHFFFAOYSA-N 2-(methylamino)pyrimidin-5-ol Chemical compound CNC1=NC=C(O)C=N1 WQWNWDNCJLEPJK-UHFFFAOYSA-N 0.000 description 1
- XOCCSJLRSSDCLM-UHFFFAOYSA-N 2-chloro-5-phenylmethoxypyrimidine Chemical compound C1=NC(Cl)=NC=C1OCC1=CC=CC=C1 XOCCSJLRSSDCLM-UHFFFAOYSA-N 0.000 description 1
- IJJJSNBMFDDFBC-UHFFFAOYSA-N 2-cyanoethyl acetate Chemical compound CC(=O)OCCC#N IJJJSNBMFDDFBC-UHFFFAOYSA-N 0.000 description 1
- HELKFYIVNMKWJJ-UHFFFAOYSA-N 2-cyanopropanedioic acid Chemical compound OC(=O)C(C#N)C(O)=O HELKFYIVNMKWJJ-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- AEOZCEMLLBCHQZ-UHFFFAOYSA-N 2-hydroxypropanimidamide;hydrochloride Chemical compound Cl.CC(O)C(N)=N AEOZCEMLLBCHQZ-UHFFFAOYSA-N 0.000 description 1
- NFNOAHXEQXMCGT-UHFFFAOYSA-N 2-phenylmethoxyacetaldehyde Chemical compound O=CCOCC1=CC=CC=C1 NFNOAHXEQXMCGT-UHFFFAOYSA-N 0.000 description 1
- DOMHHZJKRIQCDB-UHFFFAOYSA-N 3-hydroxy-6-methyl-7h-pyrrolo[3,4-b]pyridin-5-one Chemical compound C1=C(O)C=C2C(=O)N(C)CC2=N1 DOMHHZJKRIQCDB-UHFFFAOYSA-N 0.000 description 1
- DUFGYCAXVIUXIP-UHFFFAOYSA-N 4,6-dihydroxypyrimidine Chemical compound OC1=CC(O)=NC=N1 DUFGYCAXVIUXIP-UHFFFAOYSA-N 0.000 description 1
- DIRINUVNYFAWQF-UHFFFAOYSA-N 4-chloro-3-nitropyridin-2-amine Chemical compound NC1=NC=CC(Cl)=C1[N+]([O-])=O DIRINUVNYFAWQF-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- HKHLUGWPLYGWLT-UHFFFAOYSA-N 5-(benzylamino)-2-azabicyclo[2.2.1]heptane-2-carboxylic acid Chemical compound OC(=O)N1CC2CC1CC2NCC1=CC=CC=C1 HKHLUGWPLYGWLT-UHFFFAOYSA-N 0.000 description 1
- YUEKWNYGXNDQRO-UHFFFAOYSA-N 5-hydroxypyridine-2-carbonitrile Chemical compound OC1=CC=C(C#N)N=C1 YUEKWNYGXNDQRO-UHFFFAOYSA-N 0.000 description 1
- QEQPDZQLHGOYMO-UHFFFAOYSA-N 5-oxo-2-azabicyclo[2.2.1]heptane-2-carboxylic acid Chemical compound C1C2N(C(=O)O)CC1C(=O)C2 QEQPDZQLHGOYMO-UHFFFAOYSA-N 0.000 description 1
- SDNRVTUJTDSGFP-UHFFFAOYSA-N 6-azaspiro[2.4]hept-1-en-4-ylcarbamic acid Chemical compound OC(=O)NC1CNCC11C=C1 SDNRVTUJTDSGFP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 108091011108 ATP binding proteins Proteins 0.000 description 1
- 102000021527 ATP binding proteins Human genes 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001232615 Acinetobacter baumannii ATCC 19606 = CIP 70.34 = JCM 6841 Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 241001136175 Burkholderia pseudomallei Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- BZKFMUIJRXWWQK-UHFFFAOYSA-N Cyclopentenone Chemical compound O=C1CCC=C1 BZKFMUIJRXWWQK-UHFFFAOYSA-N 0.000 description 1
- 101710190437 Cytotoxin 3 Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940127266 GyrB and ParE Drugs 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 101710113864 Heat shock protein 90 Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004133 Sodium thiosulphate Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- FJAQNRBDVKIIKK-LFLQOBSNSA-N [(3r,4s,5r,6s)-6-[8-chloro-4-hydroxy-3-[[4-hydroxy-3-(3-methylbut-2-enyl)benzoyl]amino]-2-oxochromen-7-yl]oxy-5-hydroxy-3-methoxy-2,2-dimethyloxan-4-yl] 5-methyl-1h-pyrrole-2-carboxylate Chemical compound O([C@@H]1[C@H](C(O[C@@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C=C(CC=C(C)C)C(O)=CC=4)=C(O)C3=CC=2)Cl)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 FJAQNRBDVKIIKK-LFLQOBSNSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- VITFJKNVGRZRKB-UHFFFAOYSA-N acetyl isothiocyanate Chemical compound CC(=O)N=C=S VITFJKNVGRZRKB-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000005219 aminonitrile group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 244000037640 animal pathogen Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- NDKQMNWQGHSZMJ-OLZOCXBDSA-N benzyl (1s,4r)-5-azabicyclo[2.2.1]hept-2-ene-5-carboxylate Chemical compound C([C@]1(C[C@]2([H])C=C1)[H])N2C(=O)OCC1=CC=CC=C1 NDKQMNWQGHSZMJ-OLZOCXBDSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- FJAQNRBDVKIIKK-UHFFFAOYSA-N chlorobiocin Natural products OC1C(OC=2C(=C3OC(=O)C(NC(=O)C=4C=C(CC=C(C)C)C(O)=CC=4)=C(O)C3=CC=2)Cl)OC(C)(C)C(OC)C1OC(=O)C1=CC=C(C)N1 FJAQNRBDVKIIKK-UHFFFAOYSA-N 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- JRYOZJIRAVZGMV-UHFFFAOYSA-N cyclopropanecarboximidamide;hydron;chloride Chemical compound Cl.NC(=N)C1CC1 JRYOZJIRAVZGMV-UHFFFAOYSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- XHFGWHUWQXTGAT-UHFFFAOYSA-N dimethylamine hydrochloride Natural products CNC(C)C XHFGWHUWQXTGAT-UHFFFAOYSA-N 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- VMVZGGPZNHFGKS-UHFFFAOYSA-N ethyl n-(oxomethylidene)carbamate Chemical compound CCOC(=O)N=C=O VMVZGGPZNHFGKS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004407 fluoroaryl group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007915 intraurethral administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- PELJISAVHGXLAL-UHFFFAOYSA-N iodomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCI PELJISAVHGXLAL-UHFFFAOYSA-N 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- GRFNBEZIAWKNCO-UHFFFAOYSA-N mhp Natural products OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- MJIATCLHNDSDRK-UHFFFAOYSA-N n-ethyl-4-methylpentan-2-amine Chemical compound CCNC(C)CC(C)C MJIATCLHNDSDRK-UHFFFAOYSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Substances [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-M novobiocin(1-) Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C([O-])=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-M 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical class CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- ICSNLGPSRYBMBD-CDYZYAPPSA-N pyridin-2-amine Chemical compound NC1=CC=CC=[15N]1 ICSNLGPSRYBMBD-CDYZYAPPSA-N 0.000 description 1
- IFFIJVAJJSONNZ-UHFFFAOYSA-N pyridin-3-ol Chemical compound OC1=CC=CN=C1.OC1=CC=CN=C1 IFFIJVAJJSONNZ-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- VTGOHKSTWXHQJK-UHFFFAOYSA-N pyrimidin-2-ol Chemical class OC1=NC=CC=N1 VTGOHKSTWXHQJK-UHFFFAOYSA-N 0.000 description 1
- AFHQSQTUSWXNCL-UHFFFAOYSA-N pyrimidin-5-ol Chemical compound OC1=CN=CN=C1.OC1=CN=CN=C1 AFHQSQTUSWXNCL-UHFFFAOYSA-N 0.000 description 1
- 150000005255 pyrrolopyridines Chemical class 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- BWDCBBZUYJDNJZ-UHFFFAOYSA-N quinazolin-7-ol Chemical compound C1=NC=NC2=CC(O)=CC=C21 BWDCBBZUYJDNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005469 synchrotron radiation Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- HGLKMYOTFGKEDG-IWSPIJDZSA-N tert-butyl (1r,4r,5r)-5-amino-2-azabicyclo[2.2.1]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)[C@@]2([H])C[C@@H](N)[C@]1([H])C2 HGLKMYOTFGKEDG-IWSPIJDZSA-N 0.000 description 1
- ZATXHTCUZAWODK-BDAKNGLRSA-N tert-butyl (1s,4r)-5-azabicyclo[2.2.1]hept-2-ene-5-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)[C@@]2([H])C=C[C@]1([H])C2 ZATXHTCUZAWODK-BDAKNGLRSA-N 0.000 description 1
- LGEWGFOMLJQHLL-ZJUUUORDSA-N tert-butyl (4ar,7ar)-2,3,4,4a,5,6,7,7a-octahydropyrrolo[3,4-b]pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]2CNC[C@H]12 LGEWGFOMLJQHLL-ZJUUUORDSA-N 0.000 description 1
- MOMKPLKVEIROGO-UHFFFAOYSA-N tert-butyl n-(4-chloro-3-nitropyridin-2-yl)-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)C1=NC=CC(Cl)=C1[N+]([O-])=O MOMKPLKVEIROGO-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present disclosure relates to the field of medicinal chemistry and in particular to compounds, and pharmaceutical compositions thereof, that are useful as antibiotics.
- tricyclic gyrase compounds inhibit DNA Gyrase B (GyrB) and Topoisomerase IV (ParE) enzymes.
- Related methods of treating bacterial infections and methods of making the compounds using novel intermediates are also contemplated.
- the GyrB enzymatic pocket has been characterized in detail in Wigley, D.B. et al, Nature, 351(6328), 624-629, 1991. See also, Tsai FT, et al, The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin, Proteins. 1997 May; 28(l):41-52.
- ParE enzymatic pocket has been characterized in detail in Bellon, S., et al. Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differencesin novobiocin potency against topoisomerase IV and DNA gyrase, Antimicrob. Agents Chemother. 48: 1856-1864 (2004). These references are hereby incorporated by reference in their entirety.
- Tricyclic gyrase compounds of Formula I inhibit DNA Gyrase B (GyrB) and Topoisomerase IV (ParE) enzymes.
- the compound of Formula I has the structure
- R 8 can be H or an interacting substituent having a length of about 1 A to about 5 A from the carbon attachment point on the A Ring to the terminal atom in R 8 and a width of about 3.3 A or less.
- X, Y and Z can be independently selected from the group consisting of N, CR , CR Y , and CR Z , provided that no more than two of X, Y and Z are N.
- R x can be H or an interacting substituent having a length of about 1 A to about 2 A from the carbon in CR X to the terminal atom in R .
- R can be H or an interacting substituent having a length of about 1 A to about 3 A from the carbon in CR Y to the terminal atom in R Y .
- R z can be H or an interacting substituent having a length of about 1 A to about 2 A from the carbon in CR Z to the terminal atom in R z .
- R 2 can be a 6-membered aryl or heteroaryl ring containing 0-3 O, S, or N heteroatoms, optionally substituted with 0-3 noninterfering substituents, wherein 2 adjacent noninterfering substituents on R can form one or more fused rings with the 6-membered aryl or heteroaryl ring.
- the 6-membered aryl or heteroaryl ring of R 2 has a CH at the positions immediately adjacent the position where R 2 attaches to L.
- R 4 can be:
- the optional substituent can be 0 : 3 noninterfering substituents.
- R a can be a 5-6 membered aryl or heteroaryl containing 0-3 O, S, or N heteroatoms optionally substituted with 0-3 noninterfering substituents.
- R 4 substituent does not project greater than about 3 A below the plane of the A, B and C Rings toward the GyrB/ParE binding pocket floor in the bound conformation.
- R 4 does not sterically interfere with R 2 or Z when the compound is in the bound conformation.
- Figure 1 illustrates a schematic representation of the receptor constraints on the compound, particularly, the binding modes of the tricyclic inhibitors to the GyrB/ParE active-site pocket (from crystallographic data). The measurements provided for the lengths are measured from atom center of the A Ring member to the atom center of the nearest non- hydrogen atom on the active site pocket.
- the figure indicates a length of about 6 A to about 8 A from the C atom attached to R 8 to the atom on the active site pocket; about 4 A to about 5 A from the A Ring atom of X to the atom on the active site pocket; about 4 A to about 6 A from the A Ring atom of Y to the atom on the active site pocket; and about 4 A to about 6 A from the A Ring atom of Z to the atom on the active site pocket.
- the relative positions of the R 8 , R 4 , and cyclic R 2 substituents are shown.
- the approximate shape of a cross-section of a representative GyrB/ParE active-site pocket in and above the plane of the tricyclic scaffold i.e., the A, B and C Rings
- the hatched area having unbroken lines depicts regions of the inhibitor that are covered on both surfaces by the active-site pocket.
- the approximate shape of a cross-section of a representative GyrB/ParE active-site pocket below the plane of the tricyclic scaffold is shown.
- the hatched area having dashed lines depict regions of the inhibitor that make contact with the floor surface of the active-site pocket, while the plane above the tricyclic ring system is solvent exposed.
- the approximate position of the conserved substrate-binding Asp side-chain and structural water molecule are shown in Figure 1, along with the constellation of potential hydrogen-bonds (depicted as dotted lines) observed between the tricyclic scaffold and the Asp and water.
- the solvent exposed and solvent sheltered faces of the active-site pocket are highlighted.
- the solvent refers to the in vivo surroundings of GyrB/ParE active site as part of a protein, which generally includes an aqueous environment in which the protein is situated within a cell. Also, the R 4 moiety in some aspects does not project atoms greater than about 3 A below the plane of the tricyclic ring system towards the GyrB/ParE binding pocket floor in the bound state.
- Figure 2 illustrates a schematic representation of the intramolecular constraints on the compound wherein R is a 6-membered ring. Specifically, the molecular geometry and the conformations of R-groups necessary to allow binding of tricyclic inhibitors to the GyrB/ParE active-site pockets constrain the size and composition of substituents at certain positions on the inhibitor scaffold. This figure illustrates regions of potential steric interference between the R 4 substituent and the R 2 or R z substituent in the bound conformation.
- Figure 3 illustrates an example of relative positions of a primary amine that is encompassed within R 4 when bound to GyrB/ParE. This illustration also applies to a secondary amine, which is not shown in Figure 3.
- the volume occupied by the R 4 amine with respect to the tricyclic scaffold across the amines was determined using a four point trilateration procedure based on distances between the R 4 amine and four different atoms on the tricyclic scaffold from 17 different crystal structures of complexes of E.
- faecalis GyrB with tricyclic inhibitors containing a diverse set of R 4 amines comprising a secondary or tertiary amine attached to the C Ring through the secondary or tertiary amine N and a primary or secondary amine that is not attached to the C Ring.
- the relative position of the primary (or secondary, not shown) amine would be above the plane of the tricyclic scaffold, to avoid impinging the floor of the active site.
- L is a linker that bridges R 2 to the C Ring.
- L may be O or S.
- L is O.
- L is S.
- aryl refers to optionally-substituted monocyclic and fused bicyclic hydrocarbyl moiety. Any monocyclic or fused ring bicyclic system which has the characteristics of aromaticity in terms of electron distribution throughout the ring system is included in this definition. Typically, the ring systems contain 5-12 ring member atoms.
- Heteroaryl refers to optionally-substituted aromatic monocyclic and fused bicyclic heterocycles containing one or more heteroatoms selected from N, O and S. The inclusion of a heteroatom permits inclusion of 5-membered rings as well as 6-membered rings.
- alkyl include straight- and branched-chain and cyclic monovalent substituents. Examples include methyl, ethyl, propyl, isopropyl, and cyclopropyl. Where indicated, the alkyl substituents may contain 1-10C (1 to 10 carbon atoms) such as 1-3C, 1-6C, or 1-8C.
- hydrocarbyl residue refers to a residue which contains only carbon and hydrogen.
- the hydrocarbyl residue may be saturated or unsaturated, aliphatic or aromatic, straight-chain, branched-chain, or cyclic including a single ring, a fused ring system, a bridge ring system, or a spiro ring system, or a combination hydrocarbyl groups.
- the hydrocarbyl residue when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue. Thus, when specifically noted as containing such heteroatoms, the hydrocarbyl residue may also contain heteroatoms such as O, S or N within the "backbone" of the hydrocarbyl residue.
- a hydrocarbyl group may include a combination hydrocarbyl containing moieties such as a heterocyclic group, linked to a heteroalkyl containing a combination of a straight chain alkyl and a cycloalkyl group.
- cyclic residue refers to a cyclic hydrocarbyl residue, which contains only carbon and hydrogen.
- the cyclic residue when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue.
- the heterocyclic residue may also contain heteroatoms such as O, S or N within the "backbone" of the cyclic residue.
- the cyclic residue when so stated, is a cycloaliphatic or cycloheteroaliphatic residue.
- a saturated cycloaliphatic or saturated cycloheteroaliphatic residue refers to a ring containing saturated bonds between each ring member.
- unsaturated cyclic residue refers to an at least partially unsaturated or aromatic cyclic hydrocarbyl residue, which contains only carbon and hydrogen.
- the unsaturated cyclic residue when so stated however, may contain heteroatoms over and above the carbon and hydrogen members of the substituent residue.
- the unsaturated heterocyclic residue when specifically noted as containing such heteroatoms, may also contain heteroatoms such as O, S or N within the "backbone" of the unsaturated cyclic residue.
- heterocyclic and heteroaryl groups refers to the total atoms, carbon and heteroatoms N, O and/or S, which form the ring.
- an example of a 6-membered saturated cycloheteroaliphatic ring is piperidine and an example of a 6-membered heteroaryl ring is pyridine.
- the bound conformation refers to the conformation (i.e., the spatial arrangement of atoms) the tricyclic gyrase compound would assume if it was bound to the GyrB/ParE active-site pocket in the enzyme's interior.
- the compound may interact with the active site pocket and inhibit the ATPase activity.
- some substituents interact with certain amino acids and thus the substituents' ability to rotate freely about a bond is constrained.
- more useful measurements may be made to determine distances relevant for determining the dimensions of proper substituents.
- measurements are based on the relative positions of substituents on the compound while hypothetically bound to the GyrB/ParE active-site pocket.
- references to the bound conformation with respect to the compound should not be interpreted as literally encompassing the GyrB/ParE active-site pocket in combination with the compound.
- the bound conformation is characterized via measurements derived from the three dimensional structure from x-ray crystallographic data on the inhibitor complexed with a protein construct that typically encompasses the 24 or 46 kDa ATP-binding domain of one or more representative bacterial GyrB or ParE orthologs. Given the high degree of sequence identity between GyrB and ParE enzymes in most pathogenic organisms of interest, structural information derived from a protein ortholog from any pathogen of clinical relevance should be sufficient to describe the bound conformation. Briefly, crystallographic structures are generated using the following methods: Proteins of interest (e.g., E.
- E. coli GyrB E. coli GyrB, F. tularensis ParE or E. coli ParE
- the open reading frames are cloned into an expression plasmid (e.g., pET28a), and expressed in and appropriate E. coli expression strain (e.g., BL21 (DE3)).
- E. coli expression strain e.g., BL21 (DE3)
- 24 kDa and 46 kDa ATP binding domains are cloned with a C(His) 6 tag to aid purification by metal affinity chromatography. This robust chromatography step typically yields greater than 80% pure protein.
- Polishing steps including ion exchange and size exclusion chromatography are performed as needed until satisfactory (>95%) purity is achieved.
- complexes of GyrB or ParE and the inhibitor molecule of interest are generated by mixing a stoichiometric excess of the inhibitor of interest with the recombinant protein target in solution and crystallizing the complex using established crystallization methods (typically vapor diffusion, as described in Drenth J. (1999) In Principles of protein x-ray crystallography. 2 nd ed. Springer, New York).
- x-ray diffraction data are collected on single crystals of the protein-inhibitor complexes using monochromatic x-rays generated by a rotating anode or synchrotron radiation source.
- X-ray data processing, analysis and subsequent structure solution and refinement are carried out using well established computational methods (reviewed in Drenth J. (1999) In Principles of protein x-ray crystallography. 2 nd ed. Springer, New York).
- Interacting substituents on the compound that interact with the GyrB/ParE active-site pocket include those substituents that would be located within the protein's interior when the compound is in the bound conformation. Interactions of interacting substituents generally include hydrophobic interactions (which favor the apposition of lipophilic surfaces on the inhibitor and active-site pocket), and electrostatic interactions such as Van der Waals, dipole-dipole, coulombic interactions or hydrogen-bonding between atoms on the compound and atoms in the GyrB/ParE active-site pocket. For example, R 8 , R x , R Y , and R interact with various portions of the protein's interior.
- R , R , R , or R is NH 2 or NHR (where R is, for example, a small alkyl group)
- the H atom(s) on the nitrogen may interact with electronegative atoms, such as nitrogen or oxygen, proximally located in the GyrB/ParE active-site pocket to which the compound may bind.
- R 8 , R x , R Y , and R z are non-polar (e.g., a methyl group)
- the interacting substituent may also electrostatically interact with an atom in the protein's interior via Van der Waals interactions, and desolvate complementary lipophilic surfaces in the active-site pocket to form favorable hydrophobic interactions.
- the shape and size of the active-site may place restrictions on the dimensions of compound's substituents that would be sterically compatible with the active-site pocket.
- the dimensions of a substituent may be provided and are associated with the dimensions of the pocket in which the compound would be situated if in a bound conformation.
- the length of a substituent may be given based on its distance from the atom on the tricyclic scaffold to the substituent' s atom that is positioned farthest from the tricyclic scaffold, i.e., the terminal atom. The distance is measured based on the center of a first atom such as a C on the tricyclic scaffold, to the center of the terminal atom. The distance is measured from point to point in a straight line regardless of the fact that the bonds in the substituent are not linearly aligned, such as an ethyl or OH substituent.
- the width of the R substituent may be understood with respect to the dimension of the active site pocket in which R 8 resides (R 8 pocket), and with respect to the R 8 substituent when it adopts a conformation in the R 8 pocket, when the compound in the bound conformation.
- the R 8 substituent generally projects into the R 8 pocket along an axis that projects through the C atom on the A Ring that is attached to R , and the C atom on the same ring in the meta position that shares a common C atom with the B ring when the compound is in bound conformation.
- the width of the R 8 substituent refers to the width at its widest point measured from atom center to atom center that are farthest apart approximately perpendicularly about such an axis, when the compound is in the bound conformation.
- the R substituent may be able to adopt a conformation, when the compound is in the bound conformation, having a width that does not exceed about 3.3 A.
- the NHMe moiety on R 8 has a width of approximately 2.8 A. This width is derived by summing the distance of atom center of a methyl proton oriented trans to the N-H proton perpendicularly from the axis described above, with the distance of the center of the N-H proton perpendicularly from the same axis.
- the width of a cyclopropyl substituent would be approximately 3.1 A, measured as the distance between the centers of protons on adjacent carbon atoms on opposite faces of the cyclopropyl ring.
- R 8 may be H or an interacting substituent having a length of about 1 A to about 5 A from the carbon attachment point on the A Ring to the terminal atom in R 8 and a width of about 3.3 A or less.
- the length of R 8 is appropriate for the length from the tricyclic scaffold carbon to the active site pocket based on crystallographic data, which is about 6 A to about 8 A as shown in Figure 1.
- R 8 is H, CI, F, Br, NH 2 , OH, 1-3C alkyl, amino-l-3C alkyl, aminocyclopropyl, OCH 3 , OCH 2 CH 3 , cyclopropyl, CH 2 cyclopropyl, CH 2 C1, CH 2 F, CHF 2 , CF 3 , CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 , NHNH 2 , NHOH, NHNHCH 3 , NHOCH3, NHCD 3 , SCH 3 , or NHCOH, where D is deuterium.
- R 8 is H, CI, F, Br, NH 2 , 1-3C alkyl, amino-l-3C alkyl, aminocyclopropyl, OCH 3 , OCH 2 CH 3 , cyclopropyl, CH 2 cyclopropyl, CH 2 C1, CHC1 2 , CH 2 F, CHF 2 , CF 3 , CH 2 CH 2 F, CH 2 CHF 2 , CH 2 CF 3 , NHNH 2 , NHOH, NHNHCH3, NHOCH 3 , NHCD 3 , SCH 3 , or NHCOH.
- R 8 may be H, CH 3 , CH 2 CH 3 , CI, OCH 3 , NHCD 3 , NHCH 3 , NHCH 2 CH 3 , or NH 2 , such as NHCH 3 .
- X, Y and Z may be independently selected from the group consisting of N, CR X , CR Y , and CR Z , provided that no more than two of X, Y and Z are N.
- R x may be H or is an interacting substituent having a length of about 1 A to about 2 A from the carbon in CR X to the terminal atom in R x .
- R Y may be H or an interacting substituent having a length of about 1 A to about 3 A from the carbon in CR Y to the terminal atom in R Y .
- R Y would not be a methoxy substituent because a methoxy substituent is longer than 3 A.
- R z may be H or is an interacting substituent having a length of about 1 A to about 2 A from the carbon in CR Z to the terminal atom in R z .
- These lengths of CR X , CR Y , and CR Z are appropriate in comparison to the lengths from the tricyclic scaffold carbon to the active site pocket based on crystallographic data shown in Figure 1.
- X, Y and Z are CR , CR Y , and CR Z respectively.
- R x may be H, CH 3 , CI, Br, or F, such as H or F.
- R Y may be H, CH 3 , CHF 2 , CF 3, CN, CH 2 CH 3 , CI, Br, or F, such as H, F, CI, or CF 3 .
- R z may be H, CH 3 , CI, Br, or F, such as H, CH 3 or F.
- R 2 may be useful for conferring selectivity and potency against eukaryotic ATP binding proteins, such as kinases and HSP90.
- one of the compounds' benefits includes avoiding toxicity due to off target binding, such as to a kinase, due in part to R 2 's selectivity as part of the compound.
- the compounds are not potent inhibitors for eukaryotic kinases.
- R 2 is a 6- membered aryl or heteroaryl ring containing 0-3 O, S, or N heteroatoms, optionally substituted with 0-3 noninterfering substituents, wherein 2 adjacent noninterfering substituents on R 2 may form one or more fused rings with the 6-membered aryl or heteroaryl ring.
- R may be an optionally substituted 6-membered aryl or heteroaryl ring containing 0-3 O, S, or N heteroatoms such as optionally substituted pyrimidinyl, phenyl, or pyridyl.
- R 2 is a heteroaryl ring such as 6-membered heteroaryl.
- R may be attached to L through a carbon atom in the 6-membered aryl or heteroaryl ring.
- solvent sheltered faces of the GyrB/ParE active-site pockets may restrict the size of substituents on the compound proximal those solvent sheltered faces.
- the 6-membered aryl or heteroaryl ring may contain a CH at the ring positions immediately adjacent the position where R 2 attaches to L.
- FIG. 2 illustrates R 2 as an optionally substituted 6-membered heteroaryl ring, although the positioning of the substituents also applies to a 6-membered aryl ring.
- a and E are C.
- R b and R° face the solvent in the bound conformation, and thus the substituents at this position may be varied and may include prodrugs. Cyclization between R b and R° may be permitted.
- R d is partially solvent exposed, and cyclization between R° and R d (for example, with an H-bond acceptor in the R d position) may be permitted. Large substituents such as large branched groups at R d may collide with the outer rim of the pocket.
- the optionally substituted 6-membered aryl or heteroaryl ring of R 2 in combination with the one or more fused rings formed from optional substituents may be selected from the group consisting of optionally substituted indolyl, azaindolyl, pyrimidopyridyl, quinazolinyl, quinoxalinyl, naphthyridinyl, purinyl, imidizopyridinyl, furopyridinyl, isoindolylinyl, benzodioxinyl, dihydrobenzodioxinyl, benzothiazolyl, pyrrolopyridinyl, dihydropyrrolopyridinyl, benzoimidazolyl, imidazopyridinyl, dihydroimidazopyridinyl, tetrahydroisoindolyl, chromenyl, benzthiophene, benztriazolyl, benzfur
- Solvent exposed faces of the GyrB/ParE active-site pockets allow portions of the compound to be exposed to a solvent environment when in use as illustrated in Figure 1.
- noninterfering substituents may be water soluble to afford compatibility with an aqueous solvent environment. Proportions of the substituents in the direction of a potential solvent environment are not critical but one skilled in the art would understand that sterically unhindered substituents are useful. Thus, proportions of the solvent-exposed substituents may be diverse.
- a "noninterfering substituent” is a substituent which leaves the ability of the compound of Formula I to inhibit bacterial growth of at least one type of bacterium qualitatively intact.
- the noninterfering substituent would leave the ability of the compound to provide antibacterial efficacy based on a minimum inhibitory concentration (MIC) of less than 32 ⁇ g/ml, or based on inhibition of ATPase activity of DNA Gyrase B (GyrB) or Topoisomerase IV (ParE) of less than 10 nm.
- MIC minimum inhibitory concentration
- the substituent may alter the degree of inhibition based on MIC or ATPase activity.
- R may have 0-3 noninterfering substituents on the 6-membered aryl or heteroaryl ring.
- R 2 may have a substituent selected from the group consisting of OH, C0 2 H, CN, NH 2 , Br, CI, F, S0 3 H, S0 2 H 2 , S0 2 CH 3 , SOCH 3 , NHOH, NHOCH 3 , and N0 2 .
- the nitrogen atom may be oxidized to a pyridine N-oxide; thus, an OH substituent may be in the form of an oxide, thus for example, permitting a pyridyl having an N-oxide wherein the N is a ring heteroatom.
- the CI -15 hydrocarbyl residue containing 0-5 O, S, or N heteroatoms may include a combination of hydrocarbyl groups such as a combination of aliphatic rings or chains and aromatic rings linked together.
- two adjacent noninterfering substituents on R form one or more fused rings.
- the optional substituents may occupy all positions of the R 2 ring structure that are not adjacent the linker such as one position, 1-2 positions, or 1-3 positions. In some aspects, one position is optionally substituted. These substituents may be optionally substituted with substituents similar to those listed. Of course, some substituents, such as halo, are not further substituted, as known to one skilled in the art.
- R 2 may be pyrimidinyl or pyridinyl optionally substituted with CH(OH)CH 3 , C(OH)(CH 3 ) 2 , OCH 3 , CN, CH 3 , CH 2 CH 3 , O-cyclopropyl, SCH 3 , Br, CI, F, or NH 2 .
- the noninterfering substituents on R 's 6-membered aryl or heteroaryl ring that may be solvent exposed in the bound conformation may include large substituents such as prodrugs.
- R may be selected from the substituents in the following Chart 1. Chart 1
- Figures 1 and 2 show that the compound is solvent exposed in the bound conformation along the R 4 bond axis and in a 0-90° counterclockwise sweep from the R 4 bond axis.
- Choices for prodrugs and substituents on R 4 may be varied.
- the R 4 substituent in some aspects the R 4 groups do not sterically interfere with R 2 or Z groups in the bound conformation, which is illustrated in Figure 2.
- a skilled artisan would understand that to avoid steric interference, atoms on R 4 should not approach atoms on R 2 or R z (in the bound conformation) such that the interatomic distances of the closest atoms are less than the sums of their Van der Waals radii.
- the R 4 substituent does not project greater than about 3 A below the plane of the A, B and C Rings toward the GyrB/ParE binding pocket in the bound conformation.
- "Toward the GyrB/ParE binding floor pocket” refers to not projecting greater than about 3 A below the plane within about 5-6 bonds from the point of attachment of R 4 to the scaffold.
- portions of R 4 that extend greater than about 5-6 bonds away from the point of attachment of R 4 to the C Ring may project greater than about 3 A below the plane of the A, B and C Rings as these portions are not constrained by the floor of the GyrB/ParE binding pocket.
- the distance is defined as the perpendicular distance from the plane aligned with atom centers of the tricyclic scaffold to the center of the most distal atom (from the plane) on the R 4 substituent in the bound conformation.
- R 4 may be H.
- R 4 may also be an optionally substituted OR a ; wherein R a is a 5-6 membered aryl or heteroaryl containing 0-3 O, S, or N heteroatoms optionally substituted with 0-3 noninterfering substituents.
- the ring positions adjacent the position where O attaches to R a may be substituted with small substituents such as those having 2 atoms in the backbone, such as OCH 3 , CH 3 , CH 2 CH 3 , OH, NH 2 , F, CI, Br, I, or NO. In the remaining positions, substituents can be larger and diverse as substituents in these positions are solvent exposed in the bound conformation.
- R a is an optionally substituted pyrimidinyl or pyridinyl, such as unsubstituted pyrimidinyl or pyrimidinyl substituted with CH 3 or NH 2 .
- OR a is one of the following substituents in Chart 3.
- R 4 may be an optionally substituted secondary or tertiary amine attached to the C Ring through the secondary or tertiary amine N.
- Secondary amine refers to an N-containing substituent that contains one H attached to the secondary amine N when the substituent is attached to the remainder of the molecule.
- Tertiary amine refers to an N-containing substituent that contains no H attached to the tertiary amine N when the substituent is attached to the remainder of the molecule.
- R 4 when R 4 is the optionally substituted secondary or tertiary amine attached to the C Ring through the secondary or tertiary amine N, R 4 may further comprise a primary or secondary amine, wherein the primary or secondary amine is not directly attached to the C Ring.
- Primary amine refers to an amine group that contains two H atoms attached to the primary amine N when attached to the remainder of the substituent.
- secondary amine refers to an amine group that contains one H atom attached to the secondary amine N when attached to the remainder of the substituent.
- the primary or secondary amine that is not directly attached to the C Ring may be positioned in the compound in the bound conformation wherein:
- the distance between the C or N atom of Y and the primary or secondary amine N is about 7 A to about 10.5 A;
- the distance between the C atom to which R 8 is attached and the primary or secondary amine N is about 6 A to about 9 A;
- the distance between the C atom to which R 4 is attached and the primary or secondary amine N is about 3.5 A to about 6 A; and d) the distance between the C atom to which R 2 is attached and the primary or secondary amine N is about 5 A to about 7.5 A.
- R 4 may be an optionally substituted tertiary amine that is an optionally substituted 4-14 membered saturated cycloheteroaliphatic tertiary amine ring system containing 1-3 N atoms, 0-3 O atoms and 0-1 S atoms; and wherein the 4-14 membered saturated cycloheteroaliphatic ring system is a single ring, a fused ring system, a bridge ring system, or a spiro ring system.
- R 4 may be the optionally substituted tertiary amine attached to the C ring through the tertiary amine N, wherein the optionally substituted tertiary amine contains at least one additional N separated from the tertiary amine N by 2-3 atoms.
- the atoms separating the N's need not be located in the same ring. For example, one atom separating the N's may be in a ring and the second atom may be found in a substituent, or both atoms separating the N's may be in the backbone in, or a substituent on, the same or different rings.
- the optionally substituted secondary or tertiary amine of R 4 is one of the following substituents in Chart 4.
- R 4 may be a noncyclic secondary or tertiary amine substituted with 1-2 noninterfering substituents.
- R 4 may be selected from the group consisting of optionally substituted pyrazolyl, phenyl, piperazinyl, pyridinyl, and tetrahydropyridinyl.
- R 4 may be an optionally substituted 5-10 membered unsaturated cyclic or heterocyclic residue containing 0-3 N, O or S heteroatoms.
- the optional substituents may include 0-2 optional substituents selected from the group consisting of CH 3 , NH 2 , F, CI, and CH 2 NH 2 .
- the optionally substituted 5-10 membered unsaturated cyclic or heterocyclic residue containing 0-3 N, O or S heteroatoms of R 4 is one of the following substituents in Chart 5.
- the optional substituent on R 4 may include 0-3 noninterfering substituents.
- an OH substituent may be in the form of an oxide, thus for example, permitting a pyridyl having an N-oxide wherein the N is a ring heteroatom.
- the Cl-15 hydrocarbyl residue containing 0-5 O, S, or N heteroatoms may include a combination of hydrocarbyl groups such as a combination of aliphatic rings or chains and aromatic rings linked together.
- R 4 may be selected from the substituents in the following Chart 6.
- the compound may be one of the compounds exemplified in the Examples.
- the compound may be a compound in Chart 7.
- Protecting groups are useful for chemoselectivity and are known in the art. Typical protecting groups included tert-butyloxycarbonyl (BOC) and carbobenzyloxy (Cbz). When the protecting group is BOC, an acid may be used for deprotection, protecting group is Cbz, catalytic hydrogenation may be used for deprotection. [0069] Before the treating step immediately above, the process may further comprise reacting the compound of Formula II
- G 1 and G 2 are leaving groups independently selected from the group consisting of CI, Br, F, I, SR, SOR, S0 2 R, OS0 2 R, and O- benzotriazole (OBt); wherein R may be CI -8 alkyl, aryl, or heteroaryl containing 0-5 O, S, or N atoms optionally substituted with CI -4 alkyl, CI -4 alkyloxy, CI, Br, F, I, or N0 2 , such as methyl, benzyl and p-methoxybenzyl, to make the compound having the structure
- the compounds wherein R 4 is an optionally substituted secondary or tertiary amine attached to the C Ring through the secondary or tertiary amine N may also be made using a process comprising treating
- R 2 LH under basic conditions such as with the anion of phenol, thiophenol, heteroarylhydroxy or heteroarylthiol, wherein G 2 is a leaving group selected from the group consisting of CI, Br, F, and I; and optionally further comprising, before the treating step immediately above, protecting R with a protecting group, or protecting an amine in R which is not the secondary or tertiary amine N, if present, with a protecting group; and deprotecting
- the process may further comprise reacting the compound of Formula II
- G 1 is a leaving group selected from the group consisting of CI, Br, F, and I.
- a process of making the compound wherein R 4 is an optionally substituted secondary or tertiary amine attached to the C Ring through the secondary or tertiary amine N may comprise treating
- G 1 is a leaving group derived from S0 2 halide, bis(2-oxo-3-oxazolidinyl)phosphine (BOP), or benzotriazol-l-yl-oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP), with HR 4 to make the compounds herein.
- This process may also optionally further comprise, before the treating step immediately above, protecting R 8 with a protecting group, or protecting an amine in R 4 which is not the secondary or tertiary amine N, if present, with a protecting group; and deprotecting R and R after the treating step.
- the process may further comprise reacting
- G ⁇ 1 is S0 2 halide, bis(2-oxo-3-oxazolidinyl)phosphine (BOP), or benzotriazol-l-yl- oxytripyrrolidinophosphonium hexafluorophosphate (pyBOP).
- the process may further comprise coupling
- G 1 and G 2 are leaving groups independently selected from the group consisting of SH, OH, CI, Br, F, I, SR, SOR, S0 2 R, OS0 2 R, OAr, and OBt;
- R is CI -8 alkyl, aryl, or heteroaryl;
- Ar is aryl or heteroaryl containing 0-5 O, S, or N atoms optionally substituted with Cl-4 alkyl, Cl-4 alkoxy, halo or N0 2 ;
- Bt is benzotriazole;
- R 8 is an interacting substituent having a length of about 1 A to about 5 A from the carbon attachment point on the A Ring to the terminal atom in R 8 and a width of about 3.3 A or less;
- X, Y and Z are independently selected from the group consisting of N, CR , CR , and CR respectively, provided that no more than two of X, Y and Z are N, wherein R x is H or an interacting
- the intermediate compound is an amine-protected intermediate
- one or more nitrogens in the compound may be protected with carbobenzyloxy (Cbz) or BOC.
- G 1 and G may be leaving groups independently selected from the group consisting tosylate, mesylate, trifilate, O-pyrimidine, O-phenyl and O-pyridine.
- a wide variety of amines and substituted amines can be introduced into the A Ring of the pyrimidoindole system as shown in Scheme 1.
- Ortho-fluoro-nitrobenzenes SI can be readily displaced by amines to yield the orthoamino analogs S2.
- a protecting group can be introduced by incorporation in the starting material (as in S 3b) or introduced after the fluoroaryl displacement reaction (as in S 3c).
- nitration may be used to introduce the nitro group ortho to the R 8 group S3d.
- chromatography may be used to isolate the desired isomer.
- R H, F, CI, Me, CF 3 S 3b
- R 1 H, Me, Et, Cyclopropyl
- Scheme 2 outlines the general methods for preparing a wide variety of pyridine and pyrimidine starting materials. Nitration of 4,6-dihydroxypyrimidine followed by conversion of the hydroxyl groups to a chloro group with POCl 3 affords intermediate S4c.
- the chloro is readily displaced by amines and alcohols to provide the desired intermediate
- the orthofluoro-nitroaromatics S3 are converted (Scheme 2) to indoles, and nitrogen substituted indoles S6a and S6b (pyrrolopyrimidines and pyrrolopyridines) by treatment with cyano ethyl acetate or cyanomalonate followed by reduction with zinc in acetic acid alternatively the nitro group can be reduced with many alternative reduction agents such as sodium bisulfite.
- the indole intermediates are converted to tricyclic intermediates as shown in Scheme 4.
- Reaction of an amino ester indole S6a with an acylisothiocynate followed by treatment with base provides the tricycle S8a with an SH at the 2 position and an OH in the 4 position.
- treatment with an acylisocynate followed by base provides S8b with an OH substituent at both the 2 and 4 positions of the tricycle.
- S8a can be converted to a bis-sulfone by first alkylation at the 2-position sulfur, followed by activation of the 4-position with a reagent such as BOP or mesyl chloride followed by displacement with a sulfide then oxidation to the bis-sulfone S8f with a reagent such as sulfone.
- a reagent such as BOP or mesyl chloride
- the dihydroxy core S8b can be converted to the dichloro- tricycle S8g.
- Amino nitrile indole intermediates S6b may be converted to the bissulfone by treatment with carbon disulfide and an alkoide to provide the anion of the 2,4 dithiol tricylcle. This intermediate can be alkylated in situ and then oxidized to provide the bissulfone S8f.
- either intermediate S8f or S8g may be converted to the bis- aryloxy compound 9.
- the Aryloxy group in the 4 position can be displaced by amines or alcohols to provide the desired Formula I compound when R 4 is either an amine of an alkoxide.
- protection groups on the S8 intermediates and/or the R 4 group In those cases, an additional step may be required to remove the protecting group.
- R4 is OAryl or O Heteroaryl where R4 is an amine
- the dichloro tricyclic intermediate S8g may be treated with the R 4 group first, then followed by displacement of at the 2 position with an alkoxide of R OH (Scheme 6).
- this method requires protecting groups especially when a diamine is used as the R 4 group. In these cases, removal of the protecting groups provides Formula I compound. This method is particularly useful when a costly R 2 OH group is used or the R 2 group is electron rich.
- the Formula I compounds can be prepared directly from S8a by the method in Scheme 7.
- the sulfide is coupled to an aryl halide (preferably an iodo or bromo aromatic).
- a sulfonylhalide or a coupling reagent such as BOP followed by displacement with an amine provides the desired Formula I compound.
- R 4 is an amine
- Formula I compounds where R 4 is an aryl or heteroaryl may be made as shown in Scheme 8.
- the dichloro intermediate S8g is coupled to a boronic acid using Suzuki coupling conditions.
- the resulting product is then treated with an alkoxide to provide the Formula I compound.
- R4 is aryl or heteroaryl
- Prodrugs may also be prepared from the compounds of Formula I or II.
- the term "prodrug,” as used herein, represents compounds which can be transformed in vivo to the active parent compounds defined herein.
- Examples of prodrugs for example on R 4 include NHNHCH 3 ,
- a pharmaceutically-acceptable salt, ester, or prodrug of the compounds herein is also contemplated.
- prodrugs, salts, hydrates, solvates, and polymorphs can be produced from the compounds disclosed here, and that various isotopically-substituted variants (through, e.g., substitution of deuterium for hydrogen, 13 C for carbon, 15 N for nitrogen, or 32 P for phosphorus) known as "isotopomers" can also be readily produced. All such derivatives are contemplated within the scope of this disclosure.
- Compounds herein include those structures that are set out throughout the examples, and pharmaceutically acceptable salts, esters and prodrugs thereof.
- the compound is in a pharmaceutical composition or a dosage form, wherein the pharmaceutical composition or dosage form provides an effective antibiotic amount of the compound for treating or preventing infection.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising one or more physiologically acceptable surface active agents, additional carriers, diluents, excipients, smoothing agents, suspension agents, film forming substances, and coating assistants, or a combination thereof; and a composition disclosed herein.
- Acceptable additional carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co., Easton, PA (1990), which is incorporated herein by reference in its entirety.
- Preservatives, stabilizers, dyes, sweeteners, fragrances, flavoring agents, and the like may be provided in the pharmaceutical composition.
- sodium benzoate, ascorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives.
- antioxidants and suspending agents may be used.
- alcohols, esters, sulfated aliphatic alcohols, and the like may be used as surface active agents; sucrose, glucose, lactose, starch, macrocrystalline cellulose, crystallized cellulose, mannitol, light anhydrous silicate, magnesium aluminate, magnesium metasilicate aluminate, synthetic aluminum silicate, calcium carbonate, sodium acid carbonate, calcium hydrogen phosphate, calcium carboxymethyl cellulose, and the like may be used as excipients; magnesium stearate, talc, hardened oil and the like may be used as smoothing agents; coconut oil, olive oil, sesame oil, peanut oil, soya may be used as suspension agents or lubricants; cellulose acetate phthalate as a derivative of a carbohydrate such as cellulose or sugar, or methyl
- composition refers to a mixture of a compound disclosed herein with other chemical components, such as diluents or additional carriers.
- the pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a pharmaceutical composition exist in the art including, but not limited to, oral, injection, aerosol, parenteral, and topical administration.
- pharmaceutically acceptable salts of the compounds disclosed herein are provided.
- carrier refers to a chemical compound that facilitates the incorporation of a compound into cells or tissues.
- diharmonic refers to chemical compounds diluted in water that will dissolve the composition of interest as well as stabilize the biologically active form of the compound. Salts dissolved in buffered solutions are utilized as diluents in the art. One commonly used buffered solution is phosphate buffered saline because it mimics the salt conditions of human blood. Since buffer salts can control the pH of a solution at low concentrations, a buffered diluent rarely modifies the biological activity of a compound.
- an “excipient” refers to an inert substance that is added to a composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability, etc., to the composition. A “diluent” is a type of excipient.
- physiologically acceptable refers to a carrier or diluent that does not abrogate the biological activity and properties of the compound.
- a dosage form includes those forms in which the compound is admistered per se.
- a dosage form may include a pharmaceutical composition.
- the dosage form may comprise a sufficient amount of the dimer compound to treat a bacterial infection as part of a particular administration protocol, as would be understood by those of skill in the art. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences,” Mack Publishing Co . , Easton, PA, 18th edition, 1990.
- Suitable routes of administration may, for example, include oral, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
- parenteral delivery including intramuscular, subcutaneous, intravenous, intramedullary injections, as well as intrathecal, direct intraventricular, intraperitoneal, intranasal, or intraocular injections.
- the compound can also be administered in sustained or controlled release dosage forms, including depot injections, osmotic pumps, pills, transdermal (including electrotransport) patches, and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.
- compositions may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or tabletting processes.
- compositions may be formulated in any conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, diluents, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences, above.
- injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
- Suitable excipients are, for example, water, saline, dextrose, mannitol, lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, and the like.
- the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like.
- Physiologically compatible buffers include, but are not limited to, Hanks' s solution, Ringer's solution, or physiological saline buffer. If desired, absorption enhancing preparations may be utilized.
- penetrants appropriate to the barrier to be permeated may be used in the formulation.
- compositions for parenteral administration include aqueous solutions of the active compounds in water- soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
- the composition can be formulated readily by combining the compositions of interest with pharmaceutically acceptable carriers well known in the art.
- Such carriers which may be used in addition to the cationic polymeric carrier, enable the compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained by combining the active compound with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl- cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP), e.g., Povidone.
- disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone ⁇ e.g. Crospovidone), agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
- compositions may take the form of tablets or lozenges formulated in a conventional manner. Administration to the buccal mucosa and sublingually are contemplated.
- the composition can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
- compositions well known in the pharmaceutical art for uses that include intraocular, intranasal, and intraauricular delivery.
- Suitable penetrants for these uses are generally known in the art.
- Such suitable pharmaceutical formulations are most often and preferably formulated to be sterile, isotonic and buffered for stability and comfort.
- Pharmaceutical compositions for intranasal delivery may also include drops and sprays often prepared to simulate in many respects nasal secretions to ensure maintenance of normal ciliary action.
- suitable formulations are most often and preferably isotonic, slightly buffered to maintain a pH of 5.5 to 6.5, and most often and preferably include antimicrobial preservatives and appropriate drug stabilizers.
- Pharmaceutical formulations for intraauricular delivery include suspensions and ointments for topical application in the ear. Common solvents for such aural formulations include glycerin and water.
- the compositions may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- compositions may also be formulated as a depot preparation.
- Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- a suitable pharmaceutical carrier may be a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
- a common cosolvent system used is the VPD co-solvent system, which is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
- VPD co-solvent system is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant Polysorbate 80TM, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
- the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
- co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of POLYSORBATE 80TM; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.
- Methods for treating bacterial infections may include administering a therapeutically effective amount of the therapeutic compounds as described herein. Treating a bacterial infection may also include prophylactically administering the therapeutic compounds to prevent infection or the spread of an infection in a subject at imminent risk of infection, such as a subject receiving or about to undergo surgery, an immunocompromised subject, or subject otherwise at risk of an infection if the compound was not administered.
- the compounds show inhibitory activity against a broad spectrum of bacteria including H. influenzae, E. coli, S. aureus, E. faecalis, E. facium, K. pneumonia, A. baumannii, S. pneumoniae, and P. aeruginosa.
- the compounds show activity against most resistant strains for example methicillin resistant Staphylococcus aureus (MRSA).
- MRSA methicillin resistant Staphylococcus aureus
- the compounds show broad-spectrum activity against all Category A, B, and C bacterial biodefense pathogens including B. anthracis, B. pseudomallei, B. mallei, F. tularensis and Y. psetis. See the Examples.
- the compounds have excellent relative antibiotic activity with a relatively low concentration.
- the compounds may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive and Gram-negative bacteria.
- the bacterial infection that may be treated or ameliorated is MRSA.
- compositions or pharmaceutical compositions described herein may be administered to the subject by any suitable means.
- methods of administration include, among others, (a) administration though oral pathways, which administration includes administration in capsule, tablet, granule, spray, syrup, or other such forms; (b) administration through non-oral pathways such as rectal, vaginal, intraurethral, intraocular, intranasal, or intraauricular, which administration includes administration as an aqueous suspension, an oily preparation or the like or as a drip, spray, suppository, salve, ointment or the like; (c) administration via injection, subcutaneously, intraperitoneally, intravenously, intramuscularly, intradermally, intraorbitally, intracapsularly, intraspinally, intrasternally, or the like, including infusion pump delivery; as well as (d) administration topically; as deemed appropriate by those of skill in the art for bringing the active compound into contact with living tissue.
- compositions suitable for administration include compositions where the active ingredients are contained in an amount effective to achieve its intended purpose.
- a therapeutically effective amount of a compound is an amount effective to treat a bacterial infection, for example, in a mammalian subject ⁇ e.g., a human).
- the therapeutically effective amount of the compounds disclosed herein required as a dose will depend on the route of administration, the type of animal, including human, being treated, and the physical characteristics of the specific animal under consideration. The dose can be tailored to achieve a desired effect, but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
- a therapeutically effective amount means an amount of compound effective to prevent, alleviate or ameliorate symptoms of disease or prolong the survival of the subject being treated. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- the useful in vivo dosage to be administered and the particular mode of administration will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, and the specific use for which these compounds are employed.
- the determination of effective dosage levels can be accomplished by one skilled in the art using routine pharmacological methods. Typically, human clinical applications of products are commenced at lower dosage levels, with dosage level being increased until the desired effect is achieved. Alternatively, acceptable in vitro studies can be used to establish useful doses and routes of administration of the compositions identified by the present methods using established pharmacological methods.
- dosages may range broadly, depending upon the desired effects and the therapeutic indication. Typically, dosages may be about 10 microgram/kg to about 100 mg/kg body weight, preferably about 100 microgram/kg to about 10 mg/kg body weight. Alternatively dosages may be based and calculated upon the surface area of the patient, as understood by those of skill in the art.
- the exact formulation, route of administration and dosage for the pharmaceutical compositions can be chosen by the individual physician in view of the patient's condition. (See e.g., Fingl et al. 1975, in "The Pharmacological Basis of Therapeutics", which is hereby incorporated herein by reference in its entirety, with particular reference to Ch. 1, p. 1).
- the dose range of the composition administered to the patient can be from about 0.5 to about 1000 mg/kg of the patient's body weight.
- the dosage may be a single one or a series of two or more given in the course of one or more days, as is needed by the patient.
- human dosages for compounds have been established for at least some conditions, those same dosages, or dosages that are about 0.1% to about 500%, more preferably about 25% to about 250% of the established human dosage may be used.
- a suitable human dosage can be inferred from ED 50 or ID 50 values, or other appropriate values derived from in vitro or in vivo studies, as qualified by toxicity studies and efficacy studies in animals.
- the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity or organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity).
- the magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- the daily dosage regimen for an adult human patient may be, for example, an oral dose of about 0.1 mg to 2000 mg of the active ingredient, preferably about 1 mg to about 500 mg, e.g. 5 to 200 mg.
- an intravenous, subcutaneous, or intramuscular dose of the active ingredient of about 0.01 mg to about 100 mg, preferably about 0.1 mg to about 60 mg, e.g. about 1 to about 40 mg is used.
- dosages may be calculated as the free acid.
- the composition is administered 1 to 4 times per day.
- compositions may be administered by continuous intravenous infusion, preferably at a dose of up to about 1000 mg per day.
- the compounds disclosed herein in certain situations it may be necessary to administer the compounds disclosed herein in amounts that exceed, or even far exceed, the above-stated, preferred dosage range in order to effectively and aggressively treat particularly aggressive diseases or infections.
- the compounds will be administered for a period of continuous therapy, for example for a week or more, or for months or years.
- Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the antibiotic effects, or minimal effective concentration (MEC).
- MEC minimal effective concentration
- the MEC will vary for each compound but can be estimated from in vitro data. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.
- Dosage intervals can also be determined using MEC value.
- Compositions should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90%.
- the effective local concentration of the drug may not be related to plasma concentration.
- the amount of composition administered may be dependent on the subject being treated, on the subject's weight, the severity of the infection, the manner of administration and the judgment of the prescribing physician.
- compositions disclosed herein can be evaluated for efficacy and toxicity using known methods.
- the toxicology of the compound may be established by determining in vitro toxicity towards a cell line, such as a mammalian, and preferably human, cell line. The results of such studies are often predictive of toxicity in animals, such as mammals, or more specifically, humans.
- the toxicity of particular compounds in an animal model such as mice, rats, rabbits, or monkeys, may be determined using known methods.
- the efficacy of a particular compound may be established using several recognized methods, such as in vitro methods, animal models, or human clinical trials. Recognized in vitro models exist for nearly every class of condition.
- acceptable animal models may be used to establish efficacy of chemicals to treat such conditions.
- the skilled artisan can be guided by the state of the art to choose an appropriate model, dose, and route of administration, and regime.
- human clinical trials can also be used to determine the efficacy of a compound in humans.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack may for example comprise metal or plastic foil, such as a blister pack.
- the pack or dispenser device may be accompanied by instructions for administration.
- the pack or dispenser may also be accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration. Such notice, for example, may be the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
- Compositions comprising a compound formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
- substantially pure refers to the amount of purity required for formulating pharmaceuticals, which may include, for example, a small amount of other material that will not affects the suitability for pharmaceutical use.
- the substantially pure compound contains at least about 96% of the compound by weight, such as at least about 97%, 98%, 99%, or 100% of the compound.
- the terms “approximately, “about,” and “substantially” as used herein represent an amount close to the stated amount that still performs the desired function or achieves the desired result.
- the terms “approximately,” “about” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount.
- R Cyclopropyl, Isobutyl, CH 2 OH, CHOHCH 3 , C(CH 3 ) 2 OH, CH 2 F, CHF 2 , CHF 3
- R 1 : R 2 , R 3 H or CH 3 then 2eq NaBH(OAC) 3
- the resulting heterogeneous mixture was cooled to 0 °C and H 2 0 (5.00 mL) was carefully added to the mixture via syringe.
- the white suspension was filtered through a Celite filter aid and the pad was washed with anhydrous THF (250.0 mL).
- the filtrate as a clear solution was cooled to 0°C and then treated with triethylamine (12.8 mL, 91.6 mmol) and CbzCl (10.3 mL, 68.7 mmol) in that order.
- the resulting heterogeneous mixture including a white precipitate was slowly warmed to 23 °C and allowed to stir for 48 h.
- the white precipitates were filtered by reduced pressure and the resulting clear solution was concentrated in vacuo.
- the resulting heterogeneous mixture was treated with saturated sodium carbonate (aq.) (250 mL) and filtered under reduced pressure to remove a white solid.
- the filtrate was extracted with ethyl acetate (250 mL ⁇ 3) and the organic extracts were washed with brine, dried over magnesium sulfate and concentrated in vacuo.
- the crude material as colorless oil was purified by column chromatography (SiC1 ⁇ 2, EtOAc:n-Hex 1:2 (v/v)) to provide the title compound B14 (2.99 g, 12.2 mmol, 75 %) as a colorless oil.
- the heterogeneous mixture was cooled to 0 °C and quenched with saturated sodium bicarbonate (aq.) (150 mL). The mixture was extracted with ethyl acetate (200 mL ⁇ 3) and the organic extracts were washed with brine, dried over magnesium sulfate and concentrated in vacuo.
- the crude material as clear yellow oil was purified by column chromatography (Si0 2 , EtOAc:n-Hex. 1:2 (v/v)) to provide the title compound B15 (0.964 g, 2.73 mmol, 91 %) as a white solid.
- the subtitle compound D30 was synthesised using the same method described for the above compound starting with bis-sulfone and (R)-2-azaspiro[3.3]heptan-5- amine (the diamine was prepared from chiro column seperation from commercially available
- the subtitle compound D32 was synthesised using the same method described for the above compound starting with bis-sulfone and (l S,5R,6R)-3- azabicyclo[3.2.0]heptan-6-amine (the diamine was prepared according patent procedure PCT Int. Appl. (1994), WO 9415933 Al 19940721 and the separation from chiro column).
- LC- MS M+l : 435.21.
- the subtitle compound D34 was synthesized using the same method described for the above compound starting with bis-sulfone and (lS,5R,6R)-l-methyl-3- azabicyclo[3.2.0]heptan-6-amine (the diamine was prepared according patent procedure WO 2001053273 Al and the separation from chiro column).
- the subtitle compound D36 was synthesized using the same method described for the above compound starting with bis-sulfone and (3aR,6aR)-3a- methyloctahydropyrrolo[3,4-b]pyrrole (the diamine was prepared according patent procedure from US5202337 (A) and the separation from chiro column).
- the subtitle compound D44 was synthesized using the method described above starting with (lR,4R,5R)-2-azabicyclo[2.2.1]heptan-5-amine and 3-hydroxy-6-methyl- 6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one.
- LC-MS M+l : 489.22.
- the subtitle compound D45 was synthesized using the method described above starting with tert-butyl 3-azabicyclo[3.1.0]hexan-6-ylcarbamate and 5-( 1 -methyl- 1H- tetrazol-5- l)pyridin-3-ol.
- the subtitle compound D46 was synthesized using the method described above starting with (6R)-3-azabicyclo[3.2.0]heptan-6-amine and 2-aminopyrimidin-5-ol.
- the subtitle compound D43 was synthesized using the same method described for the above compound starting with bis-sulfone and tert-butyl 3- azabicyclo[3.1.0]hexan-6-ylcarbamate.
- LC-MS M+l
- the subtitle compound D51 was synthesized using the same method described for the above compound starting with bis-sulfone and (lS,4R)-6- azaspiro[3.4]octan-l -amine.
- the subtitle compound D53 was synthesized using the same method described for the above compound starting with bis-sulfone and (3aR,4R,6aS)- octahydrocyclopenta[c]pyrrol-4-amine.
- LC-MS M+1 : 449.21.
- the subtitle compound D55 was synthesized using the same method described for the above compound starting with bis-sulfone and (4aR,7aR)-tert-butyl octahydro-lH-pyrrolo[3,4-b]pyridine-l-carboxylate.
- LC-MS M+1 : 449.23.
- the subtitle compound D57 was synthesized using the same method described for the above compound starting with bis-sulfone, quinazolin-7-ol and (1 S,5R,6R)- -azabicyclo[3.2.0]heptan-6-amine.
- LC-MS M+l : 471.26.
- the subtitle compound D59 was synthesized using the same method described for the above compound starting with bis-sulfone, l,5-naphthyridin-3-ol and
- the subtitle compound D61 was synthesized using the same method described for the above compound starting with bis-sulfone, l ,5-naphthyridin-3-ol and tert- butyl 3-azabicyclo[3.1.0]hexan-6-ylcarbamate.
- LC-MS M+l : 457.20.
- the subtitle compound D65 was synthesized using the same method described for the above compound starting with bis-sulfone, 5-hydroxypicolinonitrile and
- the subtitle compound D67 was synthesized using the method described above starting with 3-fluoro-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)pyridine.
- LC-MS M+1 : 420.16.
- the subtitle compound D73 was synthesized using the method described above starting with 3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2-amine.
- the subtitle compound D98 was synthesized using the same method described for the above compound starting with bis-sulfone, 2-aminopyrimidin-5-ol and (lR,4R,5R)-2-azabicyclo[2.2.1]heptan-5-amine (the diamine was prepared according patent procedure Eur. Pat. Appl. (1990), EP 357047 Al 19900307).
- the subtitle compound D99 was synthesized using the same method described for the above compound starting with bis-sulfone, 2-aminopyrimidin-5-ol and tert- butyl (lR,5S,6r)-3-azabicyclo[3.1.0]hexan-6-ylcarbamate.
- LC-MS M+l : 440.15.
- the subtitle compound D102 was synthesized using the same method described for the above compound starting with bis-sulfone and tert-butyl (lR,4R,5R)-2- azabicyclo[2.2.1]heptan-5-ylcarbamate.
- LC-MS M+l : 449.21.
- N-methyl-2,4-bis(2-methylpyrimidin-5-yIoxy)-9H-pyrimido[4,5- b]indol-8-amine To the solution of compound (D122)(100 mg, 0.37 mmol) in NMP (5 ml) was added 2-methylpyrimidine-5-ol (100 mg, 0.9 mmol) and potassium carbonate (43.6 mg, 0.31 mmol). It was then heated at 180 °C under microwave condition for 15 minutes. The mixture was then purified through HPLC to afford the title compound D123 as yellow solid (80 mg, 52%). LC-MS : M+l : 415.15.
- the subtitle compound D125 was synthesized using the same method described for the above compound starting with bis-sulfone, 2-(l-hydroxyethyl)pyrimidin-5- ol and l-methyl-3-azabicyclo[3.2.0]heptan-6-amine (the diamine was prepared in accordance with the procedure described in PCT Int. Appl. (1994), WO 9415933 Al 19940721).
- Colonies of H. influenzae, E. coli, S. aureus, A.baumannii, S. pneumoniae, P. aeruginosa, and B. thailandensis were picked from overnight plates and resuspended in 3 mL DPBS solution. Absorbance was read at 600 nM and suspensions were diluted to an OD of O.l .
- Sa S. aureus
- Spn S. pneumoniae
- Ec E. coli
- Ab A. baumannii
- Kpn K. pneumoniae
- Pa P. aeruginosa
- Bt B. thailandensis
- Ft F. tularensis
- Yp Y. pestis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453011P | 2011-03-15 | 2011-03-15 | |
PCT/US2012/029104 WO2012125746A1 (fr) | 2011-03-15 | 2012-03-14 | Inhibiteurs de la gyrase tricyclique |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2686320A1 true EP2686320A1 (fr) | 2014-01-22 |
EP2686320B1 EP2686320B1 (fr) | 2016-05-18 |
Family
ID=45879060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12710633.4A Active EP2686320B1 (fr) | 2011-03-15 | 2012-03-14 | Inhibiteurs de la gyrase tricyclique |
Country Status (15)
Country | Link |
---|---|
US (2) | US9732083B2 (fr) |
EP (1) | EP2686320B1 (fr) |
JP (1) | JP6140083B2 (fr) |
KR (2) | KR20140059164A (fr) |
CN (1) | CN103562208B (fr) |
AR (1) | AR085806A1 (fr) |
AU (1) | AU2012229997B2 (fr) |
BR (1) | BR112013023266B8 (fr) |
CA (1) | CA2829939C (fr) |
IL (1) | IL228220A (fr) |
MX (1) | MX345780B (fr) |
RU (1) | RU2626979C2 (fr) |
TW (1) | TWI527818B (fr) |
WO (1) | WO2012125746A1 (fr) |
ZA (1) | ZA201307583B (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10858360B2 (en) | 2011-03-15 | 2020-12-08 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9409906B2 (en) * | 2012-01-27 | 2016-08-09 | Universite De Montreal | Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells |
TWI639602B (zh) * | 2012-09-12 | 2018-11-01 | 默沙東藥廠 | 三環旋轉酶抑制劑 |
CN103304488B (zh) * | 2013-06-13 | 2015-12-09 | 暨明医药科技(苏州)有限公司 | 光学纯2-(1-羟基乙基)-5-羟基嘧啶的制备方法 |
AU2014318838B2 (en) * | 2013-09-11 | 2018-06-07 | Lawrence Livermore National Security, Llc | Tricyclic gyrase inhibitors |
KR20160115986A (ko) | 2014-02-03 | 2016-10-06 | 스페로 자이레이스, 인크 | 폴리믹신을 포함하는 항균성 조합 |
WO2015150337A1 (fr) * | 2014-04-01 | 2015-10-08 | Amakem Nv | Inhibiteurs de la lim kinase |
US20210070747A1 (en) | 2017-03-24 | 2021-03-11 | Taisho Pharmaceutical Co., Ltd. | 2(1h)-quinolinone derivative |
JP7344125B2 (ja) * | 2017-03-30 | 2023-09-13 | エフ. ホフマン-ラ ロシュ アーゲー | 細菌感染の治療及び予防のための新規ピリド[2,3-b]インドール化合物 |
CN108504647B (zh) * | 2018-03-09 | 2021-11-05 | 中山大学 | 一种dna促旋酶的药物结合口袋及其应用 |
JP7296992B2 (ja) * | 2018-05-28 | 2023-06-23 | エフ. ホフマン-ラ ロシュ アーゲー | 細菌感染症の処置および予防のための新規オキソキノリジン化合物 |
JP7443351B2 (ja) * | 2018-09-26 | 2024-03-05 | エフ. ホフマン-ラ ロシュ アーゲー | 細菌感染症の治療及び予防のための、置換ピリドインドール |
WO2020109190A1 (fr) | 2018-11-27 | 2020-06-04 | F. Hoffmann-La Roche Ag | Composés tricycliques pour le traitement et la prophylaxie d'une infection bactérienne |
CN113166144A (zh) | 2018-11-27 | 2021-07-23 | 豪夫迈·罗氏有限公司 | 用于治疗和预防细菌感染的芳基化合物 |
JP7531492B2 (ja) | 2018-12-20 | 2024-08-09 | エフ. ホフマン-ラ ロシュ アーゲー | 細菌感染症の処置および予防のためのオキソピリド[1,2-a]ピリミジン化合物 |
CN114763357B (zh) * | 2021-01-15 | 2024-06-18 | 中国科学院上海药物研究所 | 吲哚并嘧啶三环类化合物及其制备方法和用途 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN157280B (fr) | 1983-07-15 | 1986-02-22 | Hoechst India | |
CA1336090C (fr) | 1988-08-31 | 1995-06-27 | Isao Hayakawa | Amines cycliques a substituant spiro de derives de la quinolone |
DE4030059A1 (de) | 1990-09-22 | 1992-03-26 | Bayer Ag | Verfahren zur herstellung von 5-hydroxy-3,4,5,6-tetrahydro-pyrimidin-derivaten |
DE4032560A1 (de) | 1990-10-13 | 1992-04-16 | Bayer Ag | 7-(2,7-diazabicyclo(3.3.0)octyl)-3-chinolon- und -naphtyridoncarbonsaeure-derivate |
PT633886E (pt) | 1992-04-03 | 2001-03-30 | Upjohn Co | Aminas biciclicas-heterociclicas farmaceuticamente activas |
US5279359A (en) | 1992-06-26 | 1994-01-18 | Erickson Donald C | Rotary trisorption heat pump |
US5350791A (en) | 1992-07-02 | 1994-09-27 | Henkel Corporation | Hydrophilicizing treatment for metal objects |
US5527910A (en) | 1992-12-30 | 1996-06-18 | Cheil Foods & Chemicals, Inc. | Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria |
RU2158127C2 (ru) * | 1994-12-23 | 2000-10-27 | Варнер-Ламберт Компани | Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция |
EP0812322A1 (fr) | 1995-03-02 | 1997-12-17 | PHARMACIA & UPJOHN COMPANY | PYRIMIDO 4,5-b]INDOLES |
PT836605E (pt) * | 1995-07-06 | 2002-07-31 | Novartis Ag | Pirrolopirimidinas e processos para a sua preparacao |
AU7890598A (en) | 1996-12-27 | 1998-07-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyrimidine compounds and medicinal use thereof |
CA2275389A1 (fr) | 1997-01-08 | 1998-10-01 | Pharmacia & Upjohn Company | Amines tricycliques pharmaceutiquement actives |
EP0999826B1 (fr) | 1997-07-29 | 2004-05-06 | PHARMACIA & UPJOHN COMPANY | Formulation autoemulsifiante pour composes lipophiles |
US6147085A (en) | 1999-04-01 | 2000-11-14 | Neurogen Corporation | Aminoalkyl substituted 9H-pyridino[2,3-b] indole and 9H-pyrimidino[4,5-b] indole derivatives |
US6221875B1 (en) | 1998-04-02 | 2001-04-24 | Neurogen Corporation | Substituted 9H-pyridino [2,3-B]indole and 9H-pyrimidino [4,5-B]indole derivatives: selective neuropeptide Y receptor ligands |
EP1068207A1 (fr) | 1998-04-02 | 2001-01-17 | Neurogen Corporation | DERIVES AMINOALKYLE SUBSTITUES DE 9H-PYRIDINO 2,3-b]INDOLE ET 9H-PYRIMIDINO 4,5-b]INDOLE |
JP2000038350A (ja) | 1998-05-18 | 2000-02-08 | Yoshitomi Pharmaceut Ind Ltd | 糖尿病治療薬 |
CA2371271A1 (fr) | 1999-04-30 | 2000-11-09 | Neurogen Corporation | Derives 9h-pyrimido[4,5-b]indoles: ligands specifiques de crf1 |
KR20020067701A (ko) | 2000-01-24 | 2002-08-23 | 워너-램버트 캄파니 | 3-아미노퀴나졸린-2,4-디온 항균제 |
FR2816509B1 (fr) | 2000-11-15 | 2004-02-06 | Sod Conseils Rech Applic | Association d'inhibiteurs de calpaine et de piegeurs des formes reactives de l'oxygene |
MXPA04004019A (es) | 2001-10-31 | 2004-07-08 | Bayer Healthcare Ag | Derivados de pirimido?4,5-b?indol. |
US20030216479A1 (en) * | 2001-11-08 | 2003-11-20 | Liren Huang | Novel compositions comprising 2,2-Bis (4-hydroxy-3-methylphenyl) heptane and uses thereof |
WO2003057149A2 (fr) | 2001-12-28 | 2003-07-17 | Bayer Corporation | Heteropyrimidines et hetero-4-pyrimidones fusionnees substituees en position 4, compositions pharmaceutiques les contenant et leur utilisation dans le traitement ou la prevention de maladies et de troubles a mediation par de7¿b? |
TWI270549B (en) | 2002-12-26 | 2007-01-11 | Taisho Pharmaceutical Co Ltd | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group |
WO2004058764A1 (fr) * | 2002-12-27 | 2004-07-15 | Bayer Healthcare Ag | Derives 4-phenyl-pyrimido [4,5-b]indoles |
SI1678166T1 (sl) * | 2003-10-14 | 2009-10-31 | Univ Arizona State | Inhibitorji proteinske kinaze |
US20090143399A1 (en) * | 2003-10-14 | 2009-06-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20080051414A1 (en) | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
US20090099165A1 (en) | 2003-10-14 | 2009-04-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
JP2006036762A (ja) | 2004-06-25 | 2006-02-09 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
JP2007161585A (ja) | 2004-06-25 | 2007-06-28 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
CN101189239A (zh) | 2005-04-28 | 2008-05-28 | 休普基因公司 | 蛋白激酶抑制剂 |
ATE411300T1 (de) * | 2005-08-05 | 2008-10-15 | Hybrigenics Sa | Neue cysteine protease hemmers und ihre therapeutische anwendungen |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
JP2007169216A (ja) | 2005-12-22 | 2007-07-05 | Taisho Pharmaceut Co Ltd | 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体 |
EP2049106A2 (fr) | 2006-07-14 | 2009-04-22 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
US20080207632A1 (en) | 2006-10-31 | 2008-08-28 | Supergen, Inc. | Protein kinase inhibitors |
US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
US7982035B2 (en) | 2007-08-27 | 2011-07-19 | Duquesne University Of The Holy Spirit | Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof |
US7960400B2 (en) * | 2007-08-27 | 2011-06-14 | Duquesne University Of The Holy Ghost | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof |
JP2011509931A (ja) | 2008-01-14 | 2011-03-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 癌を処置するための組成物および方法 |
US9079896B2 (en) * | 2008-08-02 | 2015-07-14 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
WO2011056739A1 (fr) | 2009-11-03 | 2011-05-12 | Glaxosmithkline Llc | Composés et procédés |
US9732083B2 (en) | 2011-03-15 | 2017-08-15 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
TWI639602B (zh) * | 2012-09-12 | 2018-11-01 | 默沙東藥廠 | 三環旋轉酶抑制劑 |
AU2014318838B2 (en) * | 2013-09-11 | 2018-06-07 | Lawrence Livermore National Security, Llc | Tricyclic gyrase inhibitors |
WO2016067009A1 (fr) * | 2014-10-28 | 2016-05-06 | Redx Pharma Plc | Composés présentant une activité contre les bactéries et les mycobactéries |
-
2012
- 2012-03-14 US US13/496,188 patent/US9732083B2/en active Active
- 2012-03-14 EP EP12710633.4A patent/EP2686320B1/fr active Active
- 2012-03-14 JP JP2013558143A patent/JP6140083B2/ja active Active
- 2012-03-14 KR KR1020137026970A patent/KR20140059164A/ko not_active Application Discontinuation
- 2012-03-14 AU AU2012229997A patent/AU2012229997B2/en active Active
- 2012-03-14 KR KR1020197025342A patent/KR102132574B1/ko active IP Right Grant
- 2012-03-14 BR BR112013023266A patent/BR112013023266B8/pt active IP Right Grant
- 2012-03-14 MX MX2013010511A patent/MX345780B/es active IP Right Grant
- 2012-03-14 CA CA2829939A patent/CA2829939C/fr active Active
- 2012-03-14 WO PCT/US2012/029104 patent/WO2012125746A1/fr active Application Filing
- 2012-03-14 TW TW101108646A patent/TWI527818B/zh active
- 2012-03-14 RU RU2013140798A patent/RU2626979C2/ru active
- 2012-03-14 CN CN201280020849.4A patent/CN103562208B/zh active Active
- 2012-03-14 AR ARP120100830A patent/AR085806A1/es active IP Right Grant
-
2013
- 2013-09-01 IL IL228220A patent/IL228220A/en active IP Right Grant
- 2013-10-11 ZA ZA2013/07583A patent/ZA201307583B/en unknown
-
2017
- 2017-07-07 US US15/643,760 patent/US10858360B2/en active Active
Non-Patent Citations (1)
Title |
---|
See references of WO2012125746A1 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10858360B2 (en) | 2011-03-15 | 2020-12-08 | Merck Sharp & Dohme Corp. | Tricyclic gyrase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10858360B2 (en) | Tricyclic gyrase inhibitors | |
US10865216B2 (en) | Tricyclic Gyrase inhibitors | |
WO2011032050A2 (fr) | Inhibiteurs de gyrase | |
CA3063934A1 (fr) | Inhibiteurs de kinase et leurs utilisations | |
KR20220130697A (ko) | 새로운 화합물 및 그 용도 | |
AU2016269626B2 (en) | Imidazo[1,2-b][1,2,4]triazine derivatives as antiparasitic agents | |
US20230312601A1 (en) | Thiazolo[5,4-b]pyridine malt-1 inhibitors | |
JP2024523020A (ja) | Cdkキナーゼ阻害剤として使用される化合物およびその応用 | |
EP4284797A1 (fr) | Dérivés de pyrazoleamide | |
AU2022212487A9 (en) | Pyrazoleamide derivatives | |
NZ614983B2 (en) | Tricyclic gyrase inhibitors | |
WO2017198159A1 (fr) | Dérivé d'imidazole contenant un cycle de liaison | |
WO2024040009A2 (fr) | Inhibiteurs de méthionine aminopeptidase-2 et leurs procédés de préparation et leurs utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20131015 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20140819 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC Owner name: TRIUS THERAPEUTICS, INC. |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20150702 |
|
INTG | Intention to grant announced |
Effective date: 20150715 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MERCK SHARP & DOHME CORP. Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC |
|
INTG | Intention to grant announced |
Effective date: 20151201 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Ref country code: AT Ref legal event code: REF Ref document number: 800358 Country of ref document: AT Kind code of ref document: T Effective date: 20160615 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012018528 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160818 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 800358 Country of ref document: AT Kind code of ref document: T Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160819 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160919 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012018528 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170221 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170314 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170314 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170314 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120314 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160518 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160918 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602012018528 Country of ref document: DE Owner name: MERCK SHARP & DOHME LLC, RAHWAY, US Free format text: FORMER OWNERS: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, LIVERMORE, CALIF., US; MERCK SHARP & DOHME CORP., RAHWAY, N.J., US Ref country code: DE Ref legal event code: R081 Ref document number: 602012018528 Country of ref document: DE Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, LIV, US Free format text: FORMER OWNERS: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, LIVERMORE, CALIF., US; MERCK SHARP & DOHME CORP., RAHWAY, N.J., US |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: PD Owner name: MERCK SHARP & DOHME LLC; US Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: MERCK SHARP & DOHME CORP. Effective date: 20220922 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20221013 AND 20221019 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240212 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240209 Year of fee payment: 13 Ref country code: GB Payment date: 20240208 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240209 Year of fee payment: 13 |